Posted by Clinical Lab Products | Oct 11, 2011 | Cancer, Miscellaneous |
BioCurex Inc’s RECAF cancer marker blood test has been shown to detect approximately 70% of stage I, 76% of stage II, 90% of stage III, and 100% of stage IV prostate cancers all with very high specificity.
Read MorePosted by Clinical Lab Products | Aug 9, 2010 | Cancer, Miscellaneous |
Oncimmune (USA) LLC, provider of EarlyCDT-Lung, announces the publication of a study that demonstrates the clinical validity of the test.
Read MorePosted by Clinical Lab Products | Jun 29, 2010 | Cancer, Miscellaneous |
Aeterna Zentaris Inc announced a collaborative study with Almac’s Diagnostics division for the company’s doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108.
Read MorePosted by Clinical Lab Products | Jun 10, 2010 | Cancer, Molecular Diagnostics, Prostate |
Thomas Jefferson University in Philadelphia, PA and NuView Life Sciences have entered into an exclusive licensing agreement for advancing the development of a new molecular imaging compound which identifies genomic expressions linked to prostate cancer.
Read MorePosted by Clinical Lab Products | Apr 23, 2010 | Cancer, Miscellaneous |
Gen-Probe’s PROGENSA PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week.
Read More